The clinically relevant MEK inhibitor mirdametinib combined with D-cycloserine and prediction error disrupts fear memory in PTSD models

The clinically relevant MEK inhibitor mirdametinib combined with D-cycloserine and prediction error disrupts fear memory in PTSD models

Abstract This study establishes mirdametinib as the first MEK inhibitor that can undergo clinical development for psychiatric indications such as post-traumatic stress disorder (PTSD). PTSD is characterized by persistent traumatic memories with limited effective treatment options. A body of evidence...

Full description

Bibliographic Details
Main Authors: Sanket B. Raut, Fanny Joly, Nikolas K. Haass, Rajaraman Eri, Juan J. Canales, David M. Benedek, Robert J. Ursano, Luke R. Johnson
Format: Article
Language:English
Published: Nature Publishing Group 2024-12-01
Series:Translational Psychiatry
Online Access:https://doi.org/10.1038/s41398-024-03190-6

Internet

https://doi.org/10.1038/s41398-024-03190-6

Similar Items